Education
About Us
Working with TipRanks
Follow Us
Uni-Bio Science Group Ltd. (HK:0690)
:0690
0690 Stock Chart & Stats
HK$0.13
>-HK$0.01(-3.17%)
At close: 4:00 PM EST
HK$0.13
>-HK$0.01(-3.17%)
Day’s Range― - ―
52-Week RangeHK$0.05 - HK$0.17
Previous CloseN/A
Volume1.74M
Average Volume (3M)5.61M
Market Cap
HK$685.07M
Enterprise ValueHK$618.20M
Total Cash (Recent Filing)HK$170.51M
Total Debt (Recent Filing)HK$108.00M
Price to Earnings (P/E)7.5
Beta-0.05
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.37%
Share Statistics
EPS (TTM)0.01
Shares Outstanding5,971,228,000
10 Day Avg. Volume4,310,360
30 Day Avg. Volume5,609,336
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.13
Price to Sales (P/S)0.67
P/FCF Ratio12.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & Margin StrengthSustained double-digit revenue growth alongside very high gross margins and improving EBIT/EBITDA margins indicate durable product economics and pricing power. This supports long-term reinvestment in R&D and commercial expansion and underpins persistent profitability over multiple years.
Conservative Capital Structure And High ROELow leverage and a strong equity ratio provide financial flexibility to fund capex, R&D, or M&A without overreliance on external debt. A 25% ROE signals efficient use of capital, supporting sustainable shareholder returns and the ability to weather industry cycles.
Vertically Integrated China-focused Pharma ModelControl across R&D, manufacturing and commercialization enhances margin capture, supply reliability, and faster product rollout in China. A focused therapeutic franchise supports specialized sales expertise and long-term market penetration in endocrinology, strengthening competitive positioning.
Bears Say
No Operating Cash Flow In 2024Reported absence of operating cash flow despite accounting profits suggests weak cash conversion, potential working capital strain, or timing issues. Over months this can pressure liquidity, constrain R&D/capex funding, and force external financing that dilutes financial resilience.
Negative EPS GrowthAn EPS decline while revenues grow points to margin erosion drivers such as higher operating costs, one-offs, or financing impacts. If persistent, lower earnings per share can limit retained earnings for reinvestment and weaken investor confidence in long-term profit generation.
Geographic And Therapeutic Concentration RiskHeavy reliance on the China market and a narrow therapeutic focus increases exposure to local regulatory, reimbursement, and competitive shifts. Limited geographic and product diversification can amplify downside from policy changes or demand swings over the medium term.
Uni-Bio Science Group Ltd. News
0690 FAQ
What was Uni-Bio Science Group Ltd.’s price range in the past 12 months?
Uni-Bio Science Group Ltd. lowest stock price was HK$0.05 and its highest was HK$0.17 in the past 12 months.
What is Uni-Bio Science Group Ltd.’s market cap?
Uni-Bio Science Group Ltd.’s market cap is HK$685.07M.
When is Uni-Bio Science Group Ltd.’s upcoming earnings report date?
Uni-Bio Science Group Ltd.’s upcoming earnings report date is Mar 30, 2026 which is in 35 days.
How were Uni-Bio Science Group Ltd.’s earnings last quarter?
Uni-Bio Science Group Ltd. released its earnings results on Aug 28, 2025. The company reported HK$0.013 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.013.
Is Uni-Bio Science Group Ltd. overvalued?
According to Wall Street analysts Uni-Bio Science Group Ltd.’s price is currently Overvalued.
Does Uni-Bio Science Group Ltd. pay dividends?
Uni-Bio Science Group Ltd. pays a Notavailable dividend of HK$0.003 which represents an annual dividend yield of 2.37%. See more information on Uni-Bio Science Group Ltd. dividends here
What is Uni-Bio Science Group Ltd.’s EPS estimate?
Uni-Bio Science Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Uni-Bio Science Group Ltd. have?
Uni-Bio Science Group Ltd. has 5,971,228,000 shares outstanding.
What happened to Uni-Bio Science Group Ltd.’s price movement after its last earnings report?
Uni-Bio Science Group Ltd. reported an EPS of HK$0.013 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.268%.
Which hedge fund is a major shareholder of Uni-Bio Science Group Ltd.?
Currently, no hedge funds are holding shares in HK:0690
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Uni-Bio Science Group Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.30%
12-Months-Change
Fundamentals
Return on Equity
26.27%
Trailing 12-Months
Asset Growth
14.16%
Trailing 12-Months
Company Description
Uni-Bio Science Group Ltd.
Uni-Bio Science Group Ltd. (0690) is a biotechnology company based in Hong Kong, primarily engaged in the research, development, manufacturing, and commercialization of high-quality biopharmaceutical products. The company focuses on the fields of oncology, autoimmune diseases, and other therapeutic areas, providing innovative solutions through its proprietary technologies and product pipelines. Uni-Bio Science is committed to enhancing patient care and improving health outcomes by delivering cutting-edge biopharmaceuticals and engaging in collaborations that expand its market reach.
Technical Analysis
Kintor Pharmaceutical Ltd
―
3D Medicines, Inc.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―
Options Prices
Currently, No data available
---